Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.

Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Matsumoto K, Saijo N, Kudo M, Nishio K.

Mol Cancer Ther. 2011 Jan;10(1):169-77. doi: 10.1158/1535-7163.MCT-10-0544.

2.
3.

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.

Gollob JA, Wilhelm S, Carter C, Kelley SL.

Semin Oncol. 2006 Aug;33(4):392-406. Review.

PMID:
16890795
4.

Signaling pathways in hepatocellular carcinoma.

Sia D, Villanueva A.

Oncology. 2011;81 Suppl 1:18-23. doi: 10.1159/000333254. Epub 2011 Dec 22. Review.

PMID:
22212931
5.

Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.

Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R.

Aliment Pharmacol Ther. 2008 Dec 1;28(11-12):1269-77. doi: 10.1111/j.1365-2036.2008.03857.x. Epub 2008 Sep 20. Review.

6.

Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.

Ranieri G, Gadaleta-Caldarola G, Goffredo V, Patruno R, Mangia A, Rizzo A, Sciorsci RL, Gadaleta CD.

Curr Med Chem. 2012;19(7):938-44. Review.

PMID:
22214462
7.

Sorafenib: a review of its use in advanced hepatocellular carcinoma.

Keating GM, Santoro A.

Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006. Review.

PMID:
19228077
8.

Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.

Strumberg D.

Drugs Today (Barc). 2005 Dec;41(12):773-84. Review.

PMID:
16474853
9.

Selection of patients with hepatocellular carcinoma for sorafenib.

Abou-Alfa GK.

J Natl Compr Canc Netw. 2009 Apr;7(4):397-403. Review.

PMID:
19406040
10.

[Sorafenib and radiotherapy association for hepatocellular carcinoma].

Girard N, Mornex F.

Cancer Radiother. 2011 Feb;15(1):77-80. doi: 10.1016/j.canrad.2010.11.012. Epub 2011 Jan 15. Review. French.

PMID:
21239203
11.

From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.

Pang RW, Poon RT.

Oncology. 2007;72 Suppl 1:30-44. Epub 2007 Dec 13. Review.

PMID:
18087180
12.

Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.

Matsuda Y, Fukumoto M.

Med Mol Morphol. 2011 Dec;44(4):183-9. doi: 10.1007/s00795-011-0558-z. Epub 2011 Dec 17. Review.

PMID:
22179180
13.

Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.

Huynh H, Ong RW, Li PY, Lee SS, Yang S, Chong LW, Luu DA, Jong CT, Lam IW.

Anticancer Agents Med Chem. 2011 Jul;11(6):560-75. Review.

PMID:
21554207
14.

Sorafenib in liver cancer.

Woo HY, Heo J.

Expert Opin Pharmacother. 2012 May;13(7):1059-67. doi: 10.1517/14656566.2012.679930. Review.

PMID:
22519770
15.

Met as a therapeutic target in HCC: facts and hopes.

Giordano S, Columbano A.

J Hepatol. 2014 Feb;60(2):442-52. doi: 10.1016/j.jhep.2013.09.009. Epub 2013 Sep 14. Review.

16.

Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.

Kudo M.

Dig Dis. 2011;29(3):273-7. doi: 10.1159/000327558. Epub 2011 Aug 9. Review.

PMID:
21829017
17.

Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.

Kudo M.

Dig Dis. 2011;29(3):289-302. doi: 10.1159/000327562. Epub 2011 Aug 9. Review.

18.

Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.

Smolle E, Taucher V, Petru E, Haybaeck J.

Anticancer Res. 2014 Apr;34(4):1519-30. Review.

PMID:
24692678
19.

TGF-β in epithelial to mesenchymal transition and metastasis of liver carcinoma.

Reichl P, Haider C, Grubinger M, Mikulits W.

Curr Pharm Des. 2012;18(27):4135-47. Review.

PMID:
22630087
20.

Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.

Tanaka S, Arii S.

Int J Clin Oncol. 2010 Jun;15(3):235-41. doi: 10.1007/s10147-010-0083-4. Epub 2010 May 27. Review.

PMID:
20505971

Supplemental Content

Support Center